Listen
OCTAGAM 50 mg/ml (human immunoglobulin)
NEUROLOGY - New indication
Opinions on drugs -
Posted on
Mar 23 2015
Reason for request
Extension of indication
No clinical benefit demonstrated by comparison with TEGELINE and PRIVIGEN in chronic inflammatory demyelinating polyradiculoneuropathy
OCTAGAM, human immunoglobulin for intravenous administration, now has Marketing Authorisation in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
There was no proven clinical advantage compared with TEGELINE and PRIVIGEN. Its role in the therapeutic strategy is similar to that of these other immunoglobulins.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments
